All lobbying filings

THE WASHINGTON TAX & PUBLIC POLICY GROUP

Lobbying for ALLIANCE FOR BIOPHARMACEUTICAL COMPETITIVENESS AND INNOVATION · Biopharmaceutical industry

Filing 4th Quarter - Report

4th Quarter (Oct 1 - Dec 31) 2025 · District of Columbia · House · Senate · $70,000.00 income · posted Jan 13, 2026

Official filing document

Bills named in this filing 11

HR 1990
American Innovation and R&D Competitiveness Act of 2025
S 1639
American Innovation and Jobs Act
HR 1347
AIMM Act
S 559
AIMM Act
S 1688
Growing America’s Small Businesses and Manufacturing Act
HR 574
ALIGN Act
S 187
ALIGN Act
HR 1062
Growing and Preserving Innovation in America Act of 2025
S 1605
International Competition for American Jobs Act
S 2021
Close the Round-Tripping Loophole Act
HR 1
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.

Lobbying activity 1

Taxation/Internal Revenue Code

Issues related to corporate and international taxation. Issues related to OECD Pillar 1 and Pillar 2 negotiations and agreements on the taxation of global income and the potential impacts on financial reporting and on the tax base of the U.S. and its Territories. Issues related to the taxation of intellectual property income. Issues related to IRC sections 11, 41 and 174, 55, 56A, and 59, 59A, 163(j), 168(k), 250, 951A (H.R. 1990, S. 1639, H.R. 1347, S. 559, S. 1688, H.R. 574, S. 187, H.R. 1062, S. 1605, S. 2021, H.R. 1 - Sections 70301, 70302, 70303, 70321, 70322, 70323, 70331, 70341, 70342, 70361.)

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.